uniQure NV
(LTS:0EE0)
$
6.32
-0.73 (-10.35%)
Market Cap: 312.44 Mil
Enterprise Value: -55.20 Mil
PE Ratio: 0
PB Ratio: 5.60
GF Score: 73/100 Uniqure NV at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019 / 12:10PM GMT
Release Date Price:
$48.03
David Ryan Lewis
Morgan Stanley, Research Division - MD
Good morning. Before I get going, let me just read the requisite disclosures. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk.
Now I'd like to welcome you all to our first session here in this room at the 2019 Morgan Stanley Healthcare Conference. I'm one of the biotechnology analysts here, David Lewis. And I would like to welcome to the stage with me the CEO of uniQure, Matt Kapusta.
Matthew Craig Kapusta
uniQure N.V. - CEO, Interim CFO & Executive Director
Thank you.
Questions & Answers
David Ryan Lewis
Morgan Stanley, Research Division - MD
Now uniQure, of course, is a pioneer in the gene therapy space, first company ever to have a gene therapy actually approved
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot